Taclonex« Ointment is indicated for the topical treatment of psoriasis vulgaris in adults 18 years of age and above for up to 4 weeks. The maximum weekly dose should not exceed 100 g. Treatment of more than 30% body surface area is not recommended.

Taclonex« Ointment should not be applied to the face, axillae or groin.

A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. [2006.06]BACKGROUND: The calcipotriol/betamethasone dipropionate two-compound product Dovobet/Daivobet/Taclonex(LEO Pharma A/S, Ballerup, Denmark) has been shown to be safe and effective in the treatment of psoriasis for up to 8 weeks. As psoriasis is a chronic disease, long-term treatment may be required, so there is a need to investigate the safety of its use over a longer period of time. OBJECTIVES: To investigate the safety of two treatment regimens involving use of the two-compound product over 52 weeks in the treatment of patients with psoriasis... CONCLUSIONS: Treatment with the two-compound product for up to 52 weeks appears to be safe and well tolerated whether used on its own or alternating every 4 weeks with calcipotriol treatment.

Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis [Recruiting]
The purpose of this study is to determine whether using Taclonex ointment under a hydrogel
patch is more effective than using the ointment alone in treating psoriasis. Taclonex
ointment is currently FDA approved for use on psoriasis. The hydrogel patch is a type of
adhesive pad and contains no medications. It is currently FDA approved and has been shown to
be safe and virtually free of side effects. The hypothesis is that psoriatic plaques which
are treated with Taclonex ointment under a hydrogel patch will be more effectively treated
compared to psoriatic plaques treated with Taclonex alone.